Synopsis
As Congress seems closer than ever to passing a new Medicare prescription drug benefit for seniors, FRONTLINE investigates the conflict between major pharmaceutical companies and American consumers who now pay the highest drug prices in the world. Through interviews with legislators, scientists, consumers, and industry leaders, FRONTLINE examines how states like Maine and Oregon have moved to control escalating prescription drug costs in the face of strong opposition from the pharmaceutical industry, which argues reducing drug prices will ultimately reduce the number of new innovative drugs they will develop.